Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The “Staphylococcus aureus surface antigen” is not a single, defined molecular target, but refers generically to the large and diverse family of **surface-expressed proteins** found on Staphylococcus aureus. These proteins, often called **cell wall-anchored (CWA) surface proteins**, are covalently attached to the bacterial cell wall via the action of the enzyme sortase A[1][6]. Prominent among these are the **MSCRAMM family** (Microbial Surface Components Recognizing Adhesive Matrix Molecules), which includes proteins such as protein A (SpA), clumping factor A (ClfA), and the iron-regulated surface determinant proteins (IsdA/IsdB)[1][6]. Each protein mediates specific functions: adhesion to host tissues, evasion of the host immune system, biofilm formation, iron acquisition, and direct invasion of host cells[1][5][6]. These surface proteins are crucial for S. aureus virulence and pathogenesis in a variety of infections. They are recognized as important therapeutic and vaccine targets, with some being evaluated as antigens in multicomponent vaccines[1][5]. However, since “Staphylococcus aureus surface antigen” does not uniquely specify any single protein, the term is overly broad and non-specific, and thus is not optimal for drug or vaccine development targeting, where specific proteins (e.g., SpA, ClfA) are more appropriate. Caveats and notes: - **is_incorrect** is true because “Staphylococcus aureus surface antigen” is a generic, non-specific term, not a unique molecular entity. Proper targets should specify a particular surface protein, such as “Staphylococcus aureus protein A” or “Staphylococcus aureus clumping factor A”[1][6]. - The canonical name should be updated to point to a specific well-characterized surface protein for precise research, therapeutic targeting, or data structuring. - For antibody, drug, or vaccine targeting, it is critical to specify which S. aureus surface protein is being considered[1][5][6].
Blockade of adhesion to host tissues Neutralization of immune evasion mechanisms Inhibition of biofilm formation Disruption of iron uptake
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Staphylococcus aureus surface protein.